What can heart failure trialists learn from oncology trialists?

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Oncology Research

Background:

• Cardiovascular diseases (CV) and cancers are leading global causes of death, yet cardiovascular disease mortality rates have stagnated over two decades.
• Heart failure (HF) has a high 5-year mortality rate (45-55%), with limited new drug approvals (only four in the USA over 20 years).
• Cancer drug development significantly outpaces cardiovascular drug development, evidenced by higher regulatory approval rates and revenue.

Purpose of the Study:

• To evaluate the applicability of oncology clinical trial methodologies to cardiovascular research, particularly for heart failure.
• To identify strategies for streamlining cardiovascular clinical trials, reducing costs, and accelerating the delivery of novel treatments.
• To foster discussion among stakeholders, including trialists, industry, regulators, and patients, on improving cardiovascular trial efficiency.

Main Methods:

• A review of existing cardiovascular and oncology clinical trial designs and outcomes.
• Analysis of drug approval trends and revenue generation in both therapeutic areas.
• Incorporation of insights from discussions at the Cardiovascular Clinical Trialists Workshop.

Main Results:

• Cancer research utilizes smaller trials, shorter follow-up periods, and more targeted therapies compared to cardiovascular research.
• A significant disparity exists in regulatory approvals and investment between cancer drugs and cardiovascular drugs, especially for heart failure.
• The current cardiovascular clinical trial paradigm may require re-evaluation to enhance efficiency and patient benefit.

Conclusions:

• Elements of oncology research design, such as smaller, shorter trials and targeted therapies, could be adapted to improve cardiovascular clinical trials.
• Implementing oncology-inspired approaches may accelerate the development and approval of new treatments for cardiovascular diseases, particularly heart failure.
• Collaboration among clinical trialists, industry, regulatory bodies, and patients is crucial for optimizing cardiovascular trial processes.